Vertex Pharmaceuticals
Tracked across 2 events · 12 articles · First seen Apr 28, 2026 · Last active Jun 01, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
The United States — Food and Drug Administration has accepted Vertex Pharmaceuticals's Biologics License Application (BLA) for povetacicept, an investigational therapy for immunoglobulin A nephropathy (IgAN) in adults. A Prescription Drug User Fee Act (PDUFA)…
Impact: Vertex Pharmaceuticals's Biologics License Application for povetacicept has been accepted by the United States Food and and Drug Administration, moving it closer to commercialization and potentially establishing its nephrology franchise.
Jun 01, 2026 · 6 articles
100
United States — Food and Drug Administration accepted Biologics License Application Vertex PharmaceuticalsFDA accepts Vertex povetacicept BLA
90
United States — Food and Drug Administration assigned target action date Vertex PharmaceuticalsFDA accepts Vertex povetacicept BLA
NEWSDESK
Track Vertex Pharmaceuticals live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard